Orphan Drug Label Expansions: Analysis Of Subsequent Rare And Common Indication Approvals
Health Affairs · 01.01.2024 · 43 (1) · 18-26
DOI: 10.1377/hlthaff.2023.00219 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Affairs, erschienen am 01.01.2024. Verfasst von Kathleen L Miller und 1 weiteren Autor:innen. Beteiligte Einrichtung: Kathleen L. Miller (kathleen.miller@hhs.gov), Department of Health and Human Services, Washington, D.C. Hauptthemen laut MEDLINE: Orphan Drug Production, Rare Diseases. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
The Orphan Drug Act of 1983 was enacted to provide financial incentives to stimulate drug development for rare diseases. In recent years, concerns have been raised regarding these orphan drugs, including how many are being approved for both rare and common diseases and the number of subsequent indication approvals. Policy makers have suggested modifications to the Orphan Drug Act's incentives to address these concerns. In this study we investigated the approval "family trees" of orphan drugs. We found that 491 novel orphan drugs were approved between 1990 and 2022. To date, 65 percent have been approved for a single rare disease, 15 percent have been approved for multiple rare diseases, and 20 percent have been approved for both rare and common diseases. Ten percent of orphan drugs received a subsequent indication approval for a pediatric population of an orphan disease. Revenue estimates from 2021 show that one-third of the drugs approved for both rare and common indications and 6 percent of rare-only drugs were among the 200 top-selling drugs worldwide. The results have implications for the possible externalities of modifying the incentives of the Orphan Drug Act, such as a potential decrease in the initiation of programs to develop pediatric rare disease drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Kathleen L. Miller (kathleen.miller@hhs.gov), Department of Health and Human Services, Washington, D.C.
- Michael Lanthier, Food and Drug Administration, Silver Spring, Maryland.
Zitieren
APA
Miller, K. L., & Lanthier, M. (2024). Orphan Drug Label Expansions: Analysis Of Subsequent Rare And Common Indication Approvals. Health Affairs, 43(1), 18-26. https://doi.org/10.1377/hlthaff.2023.00219
Vancouver
Miller KL, Lanthier M. Orphan Drug Label Expansions: Analysis Of Subsequent Rare And Common Indication Approvals. Health Affairs. 2024;43(1):18-26. doi:10.1377/hlthaff.2023.00219
BibTeX
@article{Miller2024,
author = {Miller, Kathleen L and Lanthier, Michael},
title = {Orphan Drug Label Expansions: Analysis Of Subsequent Rare And Common Indication Approvals},
journal = {Health Affairs},
year = {2024},
volume = {43},
number = {1},
pages = {18--26},
doi = {10.1377/hlthaff.2023.00219}
}
EUVIMED